QUALITY RISK MANAGEMENT
This article was originally published in The Gold Sheet
... draft guideline Q9 from ICH represents an important step forward down the industry/regulator communication pathway. By offering a common language and systematic approach, ICH Q9 is intended to provide a practical risk management toolbox to facilitate implementation of the pharmaceutical development (Q8) and quality systems (Q10) facets of the ICH effort to evolve a more harmonized and flexible quality oversight process. A recent PQRI workshop complements the ICH effort in exploring the usefulness of the various risk management tools. FDA, meanwhile, is continuing to refine its drug inspection program on risk-based lines through its site selection model and quality systems approach. An ongoing study of FDA data along with a review of recent high-profile enforcement actions show facility ownership changes and their impact on the functionality of the quality system are a non-compliance risk factor. Regulatory flexibility for industry will hinge on assuring that the quality organization has full corporate backing. [An FDA investigator-eye view of what a good organization looks like is included along with the terms of GlaxoSmithKline’s recent consent decree with FDA].
You may also be interested in...
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.
As biotech firms begin to pilot QbD they wrestle with FDA over non-critical process parameters, postapproval changes and more. They are exploring how to define design spaces, change them, identify their edges. And they're still wondering what regulatory relief they might get in return for investing in quality-by-design studies.